CSL, Telix and more: Key reporting dates for 10 ASX 200 healthcare stocks in August

Will these results be healthy?

Medical workers examine an xray or scan in a hospital laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FY25 reporting season is up and running with the first wave of results released at the tail end of last week.

But that was just the warm-up.

In the weeks ahead, dozens of ASX-listed companies across all sectors will deliver their outcomes for the full financial year, or for the six-month period ending in June.

And that includes some of the biggest and most closely watched ASX 200 healthcare stocks.

Kicking off proceedings was Resmed CDI (ASX: RMD) – a specialist in sleep disorder treatment – with Friday's fourth quarter and full year results.

In brief, the group's FY25 revenue jumped by 10% from a year ago, which helped to fuel a 19% increase in operating profit.

The market appeared to respond favourably, with the company's share price lifting by 1% from Thursday's close to hit record highs in Friday's trading.

ResMed's share price has now risen by 16% since the start of the year, ending last week at $42.88 per share.

In comparison, the All Ordinaries Index (ASX: XAO) is up by 5.3% over the same period.

But how will the rest of the healthcare sector perform during reporting season?

Watch this space

The list below presents 10 ASX 200 healthcare stocks set to report in August.

But before diving in, there's a few important notes to consider.

Firstly, some of these dates may change as companies conclude their number crunching.

In addition, this is not a complete list. More healthcare businesses will also be revealing their results in the coming weeks.

And one final thing.

For investors tracking other sectors, reporting dates for ten leading ASX 200 mining stocks can be found here.

Similarly, a schedule for six prominent ASX 200 energy stocks is located here.

FY25 reporting dates – ASX 200 healthcare stocks

  • Thursday 14 August – Pro Medicus Ltd (ASX: PME): This imaging software provider gets the ball rolling.
  • Friday 15 August – Cochlear Ltd (ASX: COH): An iconic Aussie business specialising in implantable hearing solutions.
  • Tuesday 19 August – CSL Ltd (ASX: CSL): The healthcare sector's biggest company and third largest on the ASX.
  • Friday 22 August – A four-company event:
    • Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH): Manufacturer of respiratory care products.
    • Healius Ltd (ASX: HLS): Diagnostic services provider.
    • Telix Pharmaceuticals Ltd (ASX: TLX): Growing diagnostic radiopharmaceuticals business.
    • Sonic Healthcare Ltd (ASX: SHL): Diversified healthcare provider.
  • Monday 25 August – A double announcement:
    • Ansell Ltd (ASX: ANN): Protective personal equipment manufacturer.
    • Polynovo Ltd (ASX: PNV): Medical device developer.
  • Thursday 28 August – Ramsay Health Care Ltd Fully Paid Ord. Shrs (ASX: RHC): Owner and operator of hospitals and health care clinics across 11 countries.

Motley Fool contributor Bart Bogacz has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, PolyNovo, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Ansell, CSL, Cochlear, PolyNovo, Pro Medicus, Sonic Healthcare, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Smiling woman driving a car.
Broker Notes

Will IAG shares rise further after 50% profit surge in FY25? Macquarie delivers verdict

IAG reported a 51.3% increase in net profit to $1.36 billion in FY25 and a 19-cent final dividend.

Read more »

St Barbara share price Minder underground looks excited a he holds a nugget of gold he has discovered.
Broker Notes

What is Macquarie's price target for Evolution Mining shares after its FY25 result?

Let's find out if the broker sees more upside for this booming mining stock.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Origin, Pro Medicus, Temple & Webster, and Westpac shares are storming higher

These shares are having a strong session on Thursday. But why?

Read more »

Happy smiling young woman drinking red wine while standing among the grapevines in a vineyard.
Broker Notes

Does Macquarie rate Treasury Wine shares a buy, hold or sell after its FY25 result?

The Australia-based global wine company delivered its FY25 results on Wednesday.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Share Fallers

Why Gorilla Gold, NextDC, South32, and Telstra shares are falling today

These shares are under pressure on Thursday and dropping into the red.

Read more »

A male ASX investor on the street wearing a grey suit clenches his fist and yells yes after seeing on his ipad that the Paladin share price is going up again today
Share Market News

ASX 200 lifts to new record high as unemployment falls

Unemployment fell to 4.2% amid record-high female participation in the labour force last month.

Read more »

a geologist or mine worker looks closely at a rock formation in a darkened cave with water on the ground, wearing a full protective suit and hard hat.
Broker Notes

Up 234% in 2025, why this small-cap ASX mining stock is tipped for more outsized gains

A top broker expects more outperformance from this fast-rising ASX mining stock. But why?

Read more »

Investor holds a bull and a bear in each hand.
Opinions

Up 20% in a month, should you buy or sell Fortescue shares?

Fortescue shares have risen by almost 20% in just 4 weeks. Should you take profits or stay the course?

Read more »